Clinical significance of inter-assay discrepancy in PD-L1 evaluation for the efficacy of pembrolizumab in advanced NSCLC with high PD-L1 expression

Immune checkpoint inhibitors (ICIs), such as anti-programmed cell death receptor-1 (PD-1)/programmed cell death ligand-1 (PD-L1) antibodies, form the standard of care in advanced lung cancer. PD-L1 expression status on tumor (TCs) and immune (ICs) cells, as measured by immunohistochemistry (IHC), is a predictive biomarker of the efficacy of PD-1/PD-L1 blockade therapy [1 –3]. Multiple assays have been developed to evaluate PD-L1 expression in conjunction with a particular therapeutic agent. For advanced non-small cell lung cancer (NSCLC), the FDA has approved four assays as companion diagnostics (CDxs), viz., PD-L1 IHC 22C3 pharmDx for pembrolizumab therapy, PD-L1 IHC 28–8 pharmDx for a combination of ipilimumab and nivolumab, VENTANA PD-L1 (SP142) for atezolizumab, and VENTANA PD-L1 (SP263) for cemiplimab.

Source: Lung Cancer - April 6, 2024 Category: Cancer & Oncology Authors: Jun Miyakoshi, Tatsuya Yoshida, Jumpei Kashima, Masayuki Shirasawa, Masahiro Torasawa, Yuji Matsumoto, Ken Masuda, Yuki Shinno, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Kouya Shiraishi, Takashi Kohno, Noboru Yamamoto, Yasushi Yatabe, Takuji Suzuki Tags: Research Paper Source Type: research